Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NMR vs CRCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NMR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

NMR Overall Winner 6-Pillar Tally: NMR 5 – 1 CRCL Matrix Metrics: NMR 9 – 1 CRCL

As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Circle Internet Group, Inc. (CRCL) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas CRCL carries 42.6/100 (HOLD) at $54.80 (44.5x Forward P/E, 11.3% operating margin).

  • Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile CRCL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NMR vs CRCL
NMR NYSE Head-to-Head Winner
Nomura Holdings, Inc
Security Brokers, Dealers & Flotation Companies
$9.34
-1.74% 1D
Market Cap $28.3B
TTM Revenue $14.9B
Forward P/E 12.7x
Beta / 30D Vol 1.03β · 29% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 47.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $9.40 · SMA50: $9.68
CRCL NYSE
Circle Internet Group, Inc.
Finance Services
$54.80
-4.94% 1D
Market Cap $16.0B
TTM Revenue $3.03B
Forward P/E 44.5x
Beta / 30D Vol 2.45β · 67% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 44.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.9%), weak momentum, RSI 26
RSI-14: 26.2 · SMA20: $72.85 · SMA50: $80.97

6-Pillar Scorecard Institutional Category Breakdown (NMR 5 – 1 CRCL)

Columns: Metric · NMR · CRCL
1. Valuation Multiples NMR
Forward P/E 12.7x 44.5x
Trailing P/E 11.2x 37.5x
PEG Ratio 0.81x 6.86x
EV / Revenue 1.9x 5.3x
2. Growth & Scale NMR
Revenue Growth (YoY) +17.9% +16.9%
Earnings Growth (YoY) +13.6% +32.1%
TTM Revenue (USD) $14.9B $3.03B
Market Cap $28.3B $16.0B
3. Profitability & Quality NMR
Gross Margin 77.4% 26.6%
Operating Margin 25.1% 11.3%
Net Profit Margin 17.1% 15.3%
Return on Equity (ROE) 11.5% 13.4%
4. Balance Sheet & Cash Flow CRCL
Cash Generation (TTM) N/A $699M
Cash Flow Margin N/A 23.1%
Net Cash / Leverage $8.17 Book/Sh · 11.5% ROE $15.08 Book/Sh · 13.4% ROE
Dividend Yield 3.34% None (0.00%)
5. Options & Positioning NMR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 30.7% (<1st %ile) 96.6% (86th %ile)
Put/Call OI Skew Thin ADR Chain 1.79x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NMR
OpEx & R&D Intensity 52.3% of Rev ($7.77B) 15.3% of Rev ($464M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Capital Markets Operator Capital Markets Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NMR (9) vs CRCL (1)
Institutional Metric NMR CRCL Criterion Row Edge
Market Capitalization
Scale
$28.3B $16.0B Larger Scale NMR
Trailing P/E Ratio
Valuation
11.2x 37.5x Lower Multiple NMR
Forward P/E Ratio
Valuation
12.7x 44.5x Lower Multiple NMR
Revenue Growth (YoY)
Growth
+17.9% +16.9% Higher Growth NMR
Operating Margin (TTM)
Profitability
25.1% 11.3% Higher Margin NMR
Net Profit Margin
Profitability
17.1% 15.3% Higher Margin NMR
Return on Equity (ROE)
Capital Efficiency
11.5% 13.4% Higher ROE CRCL
52-Week Range Position
Momentum
60% ($7–$11) 5% ($50–$140) Stronger Trend NMR
Beta / 30D Volatility
Risk Regime
1.03β · 29% Vol 2.45β · 67% Vol Lower Realized Risk NMR
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite NMR
Trailing 12M Revenue (USD)
Operating Scale
$14.9B $3.03B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.4% 26.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 1.9x EV/Rev 6.86x PEG · 5.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($8.17 Book/Sh · 11.5% ROE) $699M ($15.08 Book/Sh · 13.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMR +35.01 pp
NMR: +2.36% · CRCL: -32.65%
3M Horizon NMR +28.43 pp
NMR: -1.84% · CRCL: -30.27%
6M Horizon NMR +67.33 pp
NMR: +16.69% · CRCL: -50.64%
1Y Horizon NMR +59.4 pp
NMR: +26.32% · CRCL: -33.08%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMR vs CRCL. Trailing 12-month operating profitability (NMR 25.1% vs CRCL 11.3%) and valuation multiples (NMR 12.7x vs CRCL 44.5x Forward P/E) are benchmarked directly in Pillar 4 below.

NMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.9B
Gross Margin77.4%
Op. Margin25.1%
ROE / Fwd P/E11.5% · 12.7x
CRCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.03B
Gross Margin26.6%
Op. Margin11.3%
ROE / Fwd P/E13.4% · 44.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NMR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.7%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRCL BREAKDOWN
52d in phase · OBV DISTRIBUTION
Current IV 96.6%
IV Percentile 86th %ile
Put/Call OI Skew 1.79x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $57.65 · IV 77.1%

CRCL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($5,765)

Compare $5,765 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 77.1% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $60 / $65 Bull Call Spread

Buy 1x $60C · Sell 1x $65C · 32d

Net Entry $180 Debit
T+5d @ +5% Move +$38 (+21%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $50 / $45 Bull Put Spread

Sell 1x $50P · Buy 1x $45P · 32d

Net Entry $116 Credit
Max Credit / Yield +$116 (+30.2% RoM)
Max Risk / Buffer -15.3% Cushion ($384 Mgn)
5d Edge & Liquidity 76% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $50P / $60-$70C Seagull

Sell 1x $50P · Buy 1x $60/$70C · 32d

Net Entry $60 Debit
T+5d @ +5% Move +$167 (+21.3% RoM)
Max Risk / Buffer -13.3% Put Cushion ($783 Mgn)
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NMR Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($7.77B)
90D Engineering Disclosures 0 Published
CRCL Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $16.0B market capitalization and 11.3% operating margin.
OpEx & R&D Reinvestment 15.3% of Rev ($464M)
90D Engineering Disclosures 0 Published

Investor FAQ NMR vs CRCL Key Questions & Quantitative Answers

As of Nov 17, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over Circle Internet Group, Inc. (CRCL) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NMR carries a Unified Composite Score of 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin), whereas CRCL carries 42.6/100 (HOLD) at $54.80 (44.5x Forward P/E, 11.3% operating margin). Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile CRCL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NMR leads the Growth & Scale pillar: NMR posts +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin), compared with CRCL at +16.9% YoY revenue growth and +32.1% YoY earnings growth on $3.03B TTM revenue (26.6% gross margin, 11.3% operating margin). On trailing 12-month operating scale, NMR generates $14.9B in USD-normalized revenue versus $3.03B for CRCL. In operating R&D and SG&A reinvestment, NMR deploys 52.3% of Rev ($7.77B) (0 90-day corporate R&D disclosures) versus 15.3% of Rev ($464M) (0 disclosures) for CRCL.

NMR screens cheaper on headline valuation multiples. NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin), whereas CRCL trades at 44.5x Forward P/E, 37.5x Trailing P/E, 6.86x PEG, and 5.3x EV/Revenue (23.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMR (11.5% ROE) versus CRCL (13.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk). By comparison, CRCL carries 96.6% implied volatility (86th %ile, Extreme (>80th %ile)), a 1.79x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.45β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.